3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Completed
2
Sponsor Class
INDUSTRY
2
OTHER
1
NETWORK
1
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
2
Conditions
Colorectal Neoplasms
135
Neoplasms
37
Pancreatic Neoplasms
34
Stomach Neoplasms
27
Colonic Neoplasms
23
Neoplasm Metastasis
20
Rectal Neoplasms
17
Carcinoma, Non-Small-Cell Lung
15
Esophageal Neoplasms
10
Cholangiocarcinoma
10
Adenocarcinoma
9
Parkinson Disease 4, Autosomal Dominant Lewy Body
8
Biliary Tract Neoplasms
8
Adenocarcinoma Of Esophagus
8
Ovarian Neoplasms
7
Triple Negative Breast Neoplasms
6
Gallbladder Neoplasms
6
Esophageal Squamous Cell Carcinoma
6
Gastrointestinal Neoplasms
5
Digestive System Neoplasms
5
Breast Neoplasms
5
Advanced Solid Tumors
5
Squamous Cell Carcinoma of Head and Neck
4
Solid Tumors
4
Melanoma
4
Intestinal Neoplasms
4
Carcinoma, Pancreatic Ductal
4
Carcinoma, Hepatocellular
4
Advanced Solid Tumor
4
Small Cell Lung Carcinoma
3
Interventions
Fluorouracil
3
irinotecan sucrosofate
2
Leucovorin
2
zolbetuximab
1
pembrolizumab
1
beta-D-glucosylisophosphoramide mustard
1
Drug Therapy
1
4-fluorobenzoyl-TN-14003
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
INDUSTRY
×
Metastatic Pancreatic Adenocarcinoma
×
Leucovorin
×
Clear all
NCT05383352
2025-04-30
SIRACUSA
Ipsen
Phase 1
Completed
177 enrolled
NCT02826486
2024-08-28
COMBAT
BioLineRx, Ltd.
Phase 2
Completed
80 enrolled
13 charts